Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Yukio Shimomura

Masaaki Mori

Chieko Kitada

Tsukasa Sugo

Mika Goto

Mioko Harada

Takuya Watanabe

Nobuhiro Suzuki

Taiji Asami

Shiro Takekawa

Yoshio Matsumoto

Michiko Abe

Yuka Adachi

Hirokazu Matsumoto

Koichi Kato

Yuji Ishihara

Kaneyoshi Kato

Koichi Matsumura

Yasushi Shintani

Jun Terauchi

Yoshihiro Ishibashi

Shuji Sato

Norihiko Moriya

Toshimi Nagi

Kozo Hayashi

Hiroyuki Miya

The antibody of the present invention, which specifically reacts with a partial peptide at the N-terminal region or the C-terminal region of NPW, which enables to quantify NPW with highly sensitivity and specifically. Moreover, this antibody is useful as an agent for preventing/treating infertility, renal edema, digestive ulcer, gastric hyperacidity, etc., and a diagnostic for these diseases.

Antibody against NPW

The present invention provides a ligand to GPR8, in particular polypeptides capable of binding to GPR8 or its amides or esters, or salts thereof, as well as the DNA encoding for such polypeptides. The ligand to GPR8 of the present invention is useful in developing receptor-binding assay systems with the use of a GPR8 expression system, for screening candidate compounds for drugs such as preventive/therapeutic agents for obesity, appetite stimulants, and prolactin production inhibitors.

Ligand to GPR8

The present invention aims at providing a novel polypeptide, a receptor, a DNA thereof, and the like. Specifically, the present invention provides a polypeptide having a binding ability to the protein represented by SEQ ID NO: 1 or SEQ ID NO: 3, or its amide, its ester or its salt, a polynucleotide encoding the polypeptide, an antisense polynucleotide or an antibody to the polypeptide, a screening of agent for prevention and/or treatment of cancer, obesity, etc., which comprises using the above, and the like. The polypeptide, receptor, polynucleotide, antisense polynucleotide, antibody and the like are useful for an agent of prevention and/or treatment of cancer, obesity and the like. Further, they are useful for a screening of an agent for prevention and/or treatment of cancer, obesity and the like.

Polypeptide DNA thereof and use of the same

The present invention relates to a screening method for a compound or a salt thereof that alters the binding property of MCH or a salt thereof to SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof, characterized by using MCH, a derivative or a salt thereof and SLT or a salt thereof, or a partial peptide thereof, an amide or an ester thereof, or a salt thereof. The screening method of the present invention is useful for screening an SLT agonist, which can be used as an agent for promoting appetite (eating), and an SLT antagonist, which can be used as a prophylactic and/or therapeutic agent for obesity.

Method for screening MCH receptor antagonist/agonist

The present invention provides preventive/therapeutic agents for anorexia nervosa and preventive/therapeutic agents for obesity. More specifically, the present invention provides a method and kit for screening a compound or its salt that changes the binding properties of GPR7 to a polypeptide capable of binding specifically to GPR7.

Method of screening preventives or remedies for obesity

The present invention provides a ligand to GPR8, in particular polypeptides capable of binding to GPR8 or its amides or esters, or salts thereof, as well as DNA, encoding for such polypeptides. The ligand to GPR8 of the present invention is useful in developing a receptor-binding assay system with the use of a GPR8 expression system, for screening candidate compounds for drugs such as preventive/therapeutic agents for obesity, appetite stimulants, and prolactin production inhibitors.

Peptide having appetite stimulating activity

A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Aris a cyclic group which may have substituents;

Melanin concentrating hormone antagonist

The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist which can be used not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, and the like, and an SLC-1 antagonist which can be used not only as an antiobestic agents (drug), an appetite (eating) modulator, and the like, but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Wili syndrome and the like.

Antiobestic agents methods for screening antiobestic agents and kits comprising same

A pharmaceutical composition for preventing and treating thrombosis containing, as an active component, a saccharoascorbic acid derivative such as 2,3-di-O-benzyl-D-glucosaccharoascorbic acid n-octadecanethiol ester is disclosed.

Pharmaceutical composition for preventing and treating thrombosis

Growing community of inventors

Tsukuba, Japan

Yukio Shimomura